Ipamorelin vs GHRP-2 vs GHRP-6: Selectivity in Context
Examine where ipamorelin selectivity claims came from, how GHRP-2 appetite research adds context, and why model-specific results need careful interpretation.
| Research family | Growth hormone secretagogues |
|---|---|
| Comparison focus | GH response and selectivity |
| Foundational selectivity study | Rat assays and swine, 1998 |
| Human appetite evidence | Small acute GHRP-2 study |
| Hero catalog material | Ipamorelin, 10 mg |
| Hero product | Ipamorelin |
Ipamorelin vs GHRP-6 is often reduced to a claim that one is more selective. Adding GHRP-2 makes the comparison more useful, because it exposes the difference between potency, maximum response, and selectivity. Those terms describe different experimental questions.
The best-known selectivity findings came from laboratory and animal work. Human studies add information, but they do not create a complete direct ranking of all three compounds. This guide keeps the original models visible and separates measured results from broader assumptions.
Origin story: searching for a more selective secretagogue
The 1998 ipamorelin paper described a synthetic pentapeptide identified through a chemistry program. Investigators compared growth hormone responses with established secretagogues and examined other hormone responses in swine. This work is the source of many later selectivity claims (Raun et al., 1998).
There was also interest in how related compounds could help investigate ghrelin-linked functions beyond growth hormone. A later human experiment examined GHRP-2 and food intake. That separate question matters because a GH response is not a complete account of a compound’s observed biology (Laferrère et al., 2005).
The ipamorelin research guide covers the compound individually. Here, the focus is how to read comparative evidence without losing the study design that gave each result meaning.
How ipamorelin, GHRP-2, and GHRP-6 work
These compounds are investigated as growth hormone secretagogues. The foundational ipamorelin paper used pharmacological comparisons to place its GH-releasing action with the GHRP receptor pathway. That places the comparison within a shared research area, while leaving room for different response profiles (Raun et al., 1998).
Potency means how much compound is required to produce a defined response in a given system. Maximum response describes the largest effect measured under the assay conditions. Selectivity asks how that response compares with other measured effects or targets. A compound can differ on each dimension.
For example, a lower concentration needed to reach a particular GH signal does not automatically mean a larger maximum response. Neither measurement, by itself, proves a more selective hormone profile. A clear comparison states which dimension is being measured before declaring a difference.
These definitions also explain why rankings can change with the assay. Cell type, receptor expression, sampling time, and the chosen endpoint affect the comparison. A result should retain those conditions when it moves from a study table into an article or laboratory report.
Key studies: selectivity and appetite are different endpoints
| Evidence | Model | Question addressed | Limit |
|---|---|---|---|
| Raun et al., 1998 | Rat assays and swine | GH release and comparative hormone responses | Animal selectivity findings do not establish universal human selectivity |
| Gobburu et al., 1999 | Healthy human volunteers | Ipamorelin pharmacokinetics and GH response modeling | Not a complete three-compound outcomes comparison |
| Laferrère et al., 2005 | Seven healthy men | Acute GHRP-2 effects on meal intake | Small, short-term study of one comparator |
In the swine comparison, GHRP-2 and GHRP-6 increased ACTH and cortisol, while ipamorelin’s responses were not significantly different from those observed after GHRH stimulation. This is a model-specific selectivity finding, rather than a guarantee that ipamorelin cannot affect other hormones under other conditions (Raun et al., 1998).
The human ipamorelin study examined relationships between exposure and GH response. It supports discussion of human pharmacology, but its purpose and design should not be stretched into proof of long-term functional outcomes (Gobburu et al., 1999).
In the small GHRP-2 experiment, the investigators reported increased food intake compared with saline. That result is useful when asking whether a secretagogue can affect eating behavior. It does not establish a direct appetite ranking between GHRP-2, GHRP-6, and ipamorelin (Laferrère et al., 2005).
A comparison table should therefore leave some answers open. When a study measures one compound against a control, it cannot silently become a direct comparison with two compounds that were absent. Keeping that blank space is part of accurate reporting.
Weak spots: what we don’t know
The evidence summarized here does not establish a complete long-term safety or functional-outcome ranking across all three peptides. A hormone response can be a useful experimental endpoint without proving a benefit in another tissue or a different population.
As of November 5, 2026, ipamorelin is not an FDA-approved human medicine. FDA identifies limited safety information for ipamorelin acetate and flags immunogenicity and characterization concerns. Its compounding page still lists ipamorelin acetate, GHRP-2, and GHRP-6 under 503B category 2. An early selectivity result should not be presented as a substitute for a safety assessment (FDA, 2026).
Regulatory context should also remain specific to the material and jurisdiction. This article’s discussion of FDA status concerns the United States; it does not attempt to classify every GHRP product in every country.
Handling ipamorelin and comparator peptides in the lab
Confirm each comparator’s identity and content independently. A shared research family does not make the same solvent, stock concentration, or storage assumption appropriate for every material. Use documentation that fits both the compound and the experimental system.
For example, a nominal 10 mg ipamorelin vial brought to a final volume of 2 mL gives 5 mg/mL, equal to 5,000 mcg/mL. A 0.10 mL analytical aliquot contains 500 mcg. This calculation states mass per volume, without assigning a biological effect.
On a U-100 scale, 0.10 mL is 10 volume units. For a comparison expressed in molar concentration, use the documented molecular weight and account for how peptide content is reported. Equal microgram amounts are not automatically equal numbers of molecules.
Use the reconstitution guide and calculator to check arithmetic. Record final volume, preparation date, solvent, and lot. Keep any working dilution distinct from the stock, and do not infer stability from appearance alone.
Ipamorelin vs GHRP-2 vs GHRP-6 FAQ
Does selective mean free of other effects?
No. Selectivity describes a comparison under defined conditions; it does not prove the absence of every other biological effect.
Does the GHRP-2 study show which compound changes appetite most?
No. It compared GHRP-2 with saline in a small acute human experiment, rather than testing all three peptides (Laferrère et al., 2005).
Is the GHRP pathway interchangeable with the GHRH pathway?
They are distinct research strategies. See the CJC-1295 no-DAC guide for the GHRH-related comparator context.
What is Hero Ipamorelin?
Hero Ipamorelin is Hero Peptides’ ipamorelin research material, listed as a 10 mg vial. Evaluate its lot documentation against the assay rather than borrowing clinical conclusions from another preparation.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Source.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. Source.
- Laferrère B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. Source.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. Accessed November 5, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.